IOncology

Breast reconstruction surgery offers hope for patients to regain confidence and beauty in the field of breast cancer treatment. With advances in medical technology, implant-based breast reconstruction has become a mainstream choice. However, complications related to implants remain a key concern for both surgeons and patients. At the 16th Shanghai Breast Reconstruction Conference, Dr. Benlong Yang from the Breast Surgery Department of Fudan University Shanghai Cancer Center led a session discussing "Implant Complications." Following the event, Oncology Frontier interviewed Dr. Yang to delve into key issues surrounding implant reconstruction.

From October 17-19, 2024, the 18th International Liver Cancer Association (ILCA) Annual Conference, a prestigious academic event in the global liver cancer field, took place in Toronto, Canada. Liver cancer experts from around the world convened to discuss hot topics and the latest advancements in the basics and clinical aspects of liver cancer. This conference featured the latest research findings from scholars in the global liver cancer field. This article specially compiled the significant clinical research in the field of liver cancer treatment presented at this ILCA conference for the exchange and learning of peers. Our special correspondent from "Oncology Frontier" attended the conference on-site for in-depth coverage, and more exciting content was expected to be shared!

From September 25 to 29, 2024, the 27th National Conference on Clinical Oncology and the 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was held in Xiamen. Themed "Patient-Centered, Shared Future," the conference attracted tens of thousands of oncology experts and pharmaceutical elites from home and abroad to discuss the latest advancements in cancer prevention and treatment, cutting-edge technologies, and future trends. During the conference, Oncology Frontier had the honor of interviewing Dr. Shukui Qin, one of the founders and Vice President of CSCO. In this interview, Professor Qin reflected on CSCO’s remarkable journey since its founding in 1997, including its development through three major phases: preparation, institutionalization, and cultural growth. Supported by the Party and the government, CSCO has actively promoted five core tasks: continuing medical education in clinical oncology, academic exchanges, clinical research, expert consensus formulation, and patient services, achieving remarkable progress. Professor Qin highlighted the extraordinary progress in primary liver cancer treatment, from stagnation to breakthroughs, emphasizing CSCO’s ongoing efforts to foster multidisciplinary collaboration, strengthen basic and translational research, and explore "combination strategies" to significantly improve the survival rates of liver cancer patients.

During the 2024 CACA Integrated Esophageal Cancer Academic Conference, Dr. Shaoming Wang from the Cancer Hospital Chinese Academy of Medical Sciences gave an in-depth explanation of research progress on the burden of upper gastrointestinal cancer. During the conference, Oncology Frontier had the pleasure of interviewing Professor Wang to further explore his team’s latest research findings on the global lifetime risk of gastrointestinal cancer.

From September 25 to 29, 2024, the 27th Annual National Clinical Oncology Conference and 2024 CSCO Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing CISCO Clinical Oncology Research Foundation, will be held in Xiamen. With the theme "Patient-Centered, Sharing the Future," the conference will showcase important research advancements and trends in the field, both domestically and internationally. For over two decades, CSCO has been at the forefront of clinical oncology development in China, and numerous experts and scholars have played integral roles in its evolution, growing along with CSCO. To honor this journey, Oncology Frontier has established a special column, "Growing Together with CSCO," to reflect on these experiences with Chinese scholars. In this inaugural issue, we are pleased to interview Dr. Zefei Jiang, Vice President and Secretary General of CSCO and a professor at the The Fifth Medical Center of Chinese PLA General Hospital, who shares his personal journey of growth with CSCO and highlights the exciting features of the 2024 CSCO Conference.

From September 25 to 29, 2024, the 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, were held in Xiamen. The theme of this year’s conference was “Patient-Centered, Sharing the Future,” bringing together key research advancements and developments in the field from both China and abroad. During the conference, Oncology Frontier had the pleasure of interviewing the conference chair, Dr. Ruihua Xu from Sun Yat-sen University Cancer Center. Professor Xu emphasized the importance of a patient-centered approach to cancer treatment, showcased the latest advances in immunotherapy, and highlighted future research directions and current challenges.

As one of the world's largest and most academically prestigious clinical oncology conferences, the 2024 European Society for Medical Oncology (ESMO) conference, held from September 13 to 17 in Barcelona, drew global attention. The conference revealed several important clinical study results in upper gastrointestinal tumors. Dr. Filippo Pietrantonio, an oncologist from the National Cancer Institute in Milan, Italy, shared his insights in an exclusive interview with Oncology Frontier.

Radiotherapy combined with immunotherapy has become a significant focus in the treatment of unresectable lung cancer, but many key clinical questions remain unresolved. Establishing a consensus is crucial to guide standardized clinical practice. To address these needs, Academician Jinming Yu from Shandong Cancer Hospital, Dr. Ying Cheng from Jilin Cancer Hospital, and Dr. Lian’an Chen from Chinese PLA General Hospital led a multidisciplinary effort to review evidence in this field. Together with expert members from key national organizations, they have developed the 2024 Consensus on Radiotherapy Combined with Immunotherapy for Unresectable Lung Cancer.

From October 19-20, 2024, the first stop of the "St. Gallen Breast Cancer Conference China Tour" was held in Nanjing. This series of conferences is organized by the Breast Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), with support from the Beijing Xisike Clinical Oncology Research Foundation, the Beijing Kexin Medical Development Foundation, and the Jiangsu Anti-Cancer Association. It is hosted by Jiangsu Provincial People's Hospital. SGBCC President, Prof. Michael Gnant, personally attended the event, facilitating the exchange of the latest advancements between European, Japanese, and Chinese breast cancer experts. Prof. Zefei Jiang, the President-Elect of CSCO and a member of the St. Gallen Breast Cancer International Consensus Panel, shared his insights and expressed his expectations for future cooperation between SGBCC and CSCO.

Breast cancer is one of the most common malignancies among women, and while treatment methods continue to improve, maintaining patients' quality of life while extending their survival remains a key focus in the medical community. With the emergence of oncoplastic surgery (OPS) and fat grafting techniques, the post-operative quality of life for breast cancer patients has significantly improved. At the Sixteenth Shanghai Breast Reconstruction Conference, Oncology Frontier invited Dr. Guangyu Liu from Fudan University Shanghai Cancer Center to deeply explore the latest advancements, clinical applications, and future development trends in breast reconstruction techniques. Prof. Liu shared valuable experiences and insights on how OPS helps achieve better breast shape and function, the use of fat grafting in breast reconstruction, the timing and order of reconstruction surgery with adjuvant therapy, and the future trends in breast reconstruction.